Fuda Cancer Hospital
Fuda Cancer Hospital
China, Kanton
Small intestine cancer treatment cost in China typically runs from $14,500 to $26,500 for primary surgical interventions. Expenses depend on the disease stage, specific therapy protocols, and the hospital tier. International patients can expect 60% to 80% savings compared to the United States. Guangzhou and Xiamen are leading cities providing specialized oncological care for this condition.
Typical Small Intestine Cancer Treatment Costs in China
Bookimed Expert Insight: Late-stage patients find the best value at specialized centers like Fuda Cancer Hospital. They offer over 10 minimally invasive options, including NanoKnife and cryosurgery. This is ideal for those seeking alternatives to traditional chemotherapy. For cases requiring complex radiation, Xiamen Humanity Hospital provides advanced technologies like VMAT and SBRT. These JCI-accredited facilities offer high-tech care at competitive international rates.
| China | Türkei | Österreich | |
| Strahlentherapie bei Darmkrebs | von $11,500 | von $7,000 | von $12,000 |
| Strahlentherapie bei Darmkrebs | von $10,500 | von $5,800 | von $6,921 |
| Resektion des Dünndarms | von $14,500 | von $12,150 | von $25,000 |
| Hyperthermische intraperitoneale Chemotherapie (HIPEC) | von $22,500 | von $22,500 | von $40,000 |
| Chemotherapie bei Brustkrebs | von $14,800 | von $1,200 | von $15,000 |
Bookimed erhebt keine zusätzlichen Gebühren für Dünndarmkrebs-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Dünndarmkrebs einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Dünndarmkrebs-Behandlungsreise nie allein.
Professor Shixin Liu, MD, PhD, ist Fachbereichsleiter des Onkologiezentrums. Zuvor war er Präsident des Krebskrankenhauses der Provinz Jilin und Direktor des Forschungsinstituts für Krebsprävention und -therapie. Er ist Professor der zweiten Ebene und Promotionsbetreuer. Er erhielt die Sonderzulage des Staatsrats, die 4. Auszeichnung 'National Famous Doctor (Outstanding Contribution)' sowie den Ehrentitel 'Vorbild ärztlicher Ethik'.
Er ist auf die umfassende Diagnostik und Behandlung bösartiger Tumoren spezialisiert, mit Schwerpunkt auf präziser Strahlentherapie thorakaler und abdomineller Tumoren. Er beherrscht IMRT, VMAT und SBRT bei Lungen-, Speiseröhren-, Brust- und Rektumkarzinomen.
Zu seinen Leitungsfunktionen zählen die stellvertretenden Vorsitzämter bei CMA Radiation Oncology, CACA Radiotherapy und CACA Particle Therapy. Er gehört dem Ständigen Ausschuss der CSCO an und ist stellvertretender Vorsitzender des CSCO-Expertenkomitees für Strahlenonkologie. Zudem ist er stellvertretender Vorsitzender der CPAM Radiation Oncology und Mitglied des Ständigen Ausschusses der CSMEA. Er ist Vorsitzender der Sektion Strahlenonkologie der Jilin Medical Association. Er gehört den Redaktionsbeiräten des Chinese Journal of Radiation Oncology und des Practical Journal of Cancer an.
Primary treatment for small intestine cancer in China centers on surgical resection and advanced minimally invasive therapies. High-volume oncology centers prioritize R0 resection, often using laparoscopic or robotic techniques for faster recovery. Specialized facilities also utilize local ablation and hyperthermic intraperitoneal chemotherapy to manage advanced cases.
Bookimed Expert Insight: Patient data highlights a significant trend at specialized facilities like Fuda Cancer Hospital in Guangzhou. While standard protocols follow surgery with chemotherapy, these centers successfully substitute systemic drugs with minimally invasive ablative technologies. This approach is particularly effective for stage 3 or 4 patients who cannot tolerate the toxicity of traditional chemo regimens.
Patient Consensus: Patients emphasize the importance of choosing tertiary cancer centers with high surgeon experience in rare gastrointestinal tumors. They note that securing a second pathology review and detailed molecular testing is vital for determining if immunotherapy is an option.
Tumor location within the small intestine directly dictates the surgical approach and complexity. Upper tumors in the duodenum often require intricate multi-organ procedures like the Whipple. Conversely, tumors in the jejunum or ileum typically allow for standard bowel resections and direct reattachment.
Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital in Guangzhou utilize advanced techniques like NanoKnife for tumors in anatomically complex areas. Our data shows these facilities often manage over 30,000 international patients. This specialized experience is critical for duodenal cases where traditional surgery is high-risk.
Patient Consensus: Patients note that tumors located higher in the intestine cause blockage symptoms much earlier. They emphasize asking surgeons exactly how many centimeters of the bowel will be removed.
Top Chinese oncology centers in Guangzhou and Beijing specialize in treating advanced or unresectable small intestine cancer. These JCI-accredited facilities utilize cryosurgery and NanoKnife to target inoperable tumors. Specialized multidisciplinary teams integrate hyperthermic intraperitoneal chemotherapy (HIPEC) with vascular intervention for complex cases.
Bookimed Expert Insight: Data shows Fuda Cancer Hospital has treated over 30,000 patients from 100 countries. Their focus shifts from traditional surgery to microwave hyperthermia and cryosurgery for late-stage cases. This specific focus on minimally invasive local destruction is a key differentiator for unresectable tumors.
Patient Consensus: Patients note it is vital to bring original pathology slides and imaging discs for re-staging. Seeking second opinions at high-volume academic hospitals helps confirm if a tumor is truly unresectable.
The 3C+P model for gastrointestinal cancers in China is a comprehensive multidisciplinary management strategy. It integrates traditional chemotherapy, traditional Chinese medicine, and supportive care with precision medicine. This protocol aims to reduce therapy side effects while targeting specific molecular markers in advanced tumors.
Bookimed Expert Insight: While various 3C+P versions exist, JCI-accredited facilities like Fuda Cancer Hospital emphasize technological integration. They combine traditional pillars with advanced minimally invasive therapies like Cryosurgery or NanoKnife. This high-volume expertise is critical for rare conditions like small intestine cancer. Centers like Xiamen Humanity Hospital further refine the model. They utilize precision radiotherapy techniques including IMRT and VMAT for abdominal malignancies. Patients should confirm which specific technologies are bundled into a center's 3C+P protocol before booking.
Patient Consensus: Patients note that small intestine cancer requires specific surgical expertise rather than just a general protocol label. Many emphasize bringing physical pathology slides and imaging CDs to ensure the multidisciplinary team has accurate data for planning.
Bookimed Expert Insight: While Chinese hospitals serve thousands of international patients, integration levels vary by facility. Elite centers like Fuda Cancer Hospital combine minimal interventions like cryosurgery with TCM consultation. This hybrid approach often attracts patients seeking alternatives when standard systemic chemotherapy feels too taxing.
Patient Consensus: Patients note that TCM is vital for emotional comfort and improving appetite during recovery. Most emphasize using herbs only as an add-on to surgery to avoid dangerous delays.